A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers.
Wohlford GF, Buckley LF, Kadariya D, Park T, Chiabrando JG, Carbone S, Mihalick V, Halquist MS, Pearcy A, Austin D, Gelber C, Abbate A, Van Tassell B.
Wohlford GF, et al. Among authors: austin d.
PLoS One. 2021 May 6;16(5):e0247357. doi: 10.1371/journal.pone.0247357. eCollection 2021.
PLoS One. 2021.
PMID: 33956804
Free PMC article.
Clinical Trial.